Table 1.

Baseline characteristics of 535 participants in the CArdiovascular and REnal outcome in CKD stage 2-4 patients - the FOuRth HOMburg evaluation study in Saarland, Germany

CharacteristicTotal (n=535)eGFR Range (ml/min per 1.73 m2)
89–60 (n=111)59–45 (n=184)44–30 (n=144)29–15 (n=96)
Age, yr65±1259±1265±1268±1168±11
Women219 (41)36 (32)83 (45)62 (43)38 (40)
Cardiovascular disease169 (32)18 (16)57 (31)63 (44)31 (32)
DM205 (38)38 (34)72 (39)55 (38)40 (42)
Smoker54 (10)20 (18)14 (8)12 (8)8 (8)
eGFR, ml/min per 1.73 m246±1669±752±438±423±4
Urinary albumin excretion, mg/g31 (8–191)21 (7–100)18 (6–74)45 (10–166)139 (37–685)
Phosphate, mg/dl3.4±0.73.0±0.53.3±0.53.4±0.83.8±0.7
Urinary fractional phosphate excretion, (%)22 (15–31)15 (11–20)19 (13–25)27 (20–34)39 (29–47)
PTH, pg/ml60 (42–91)46 (36–61)50 (37–67)72 (48–108)118 (71–177)
nox-PTH, pg/ml9 (7–13)8 (7–10)8 (7–11)10 (8–14)13 (10–19)
FGF-23, rU/ml99 (64–157)64 (47–89)79 (57–107)128 (92–196)179 (140–296)
sKlotho, pg/ml397 (326–485)433 (369–581)412 (344–493)374 (299–454)382 (303–459)
25-OH- vit. D3, (ng/ml)23±1323±1223±1323±1423±14
1,25-(OH)2- vit. D3, (pg/ml) 30±1236±1330±1129±1125±9
ACE-I190 (36)33 (30)74 (40)45 (31)38 (40)
At1A271 (51)65 (59)90 (49)75 (52)41 (43)
β-blockers370 (69)60 (54)123 (67)116 (81)71 (74)
Active vitamin D medication36 (7)2 (2)2 (1)14 (10)18 (19)
Statins276 (52)42 (38)98 (53)86 (60)50 (52)
  • Variables are presented as number of patients (percentage), mean±SD, or median (interquartile range), as appropriate. DM, diabetes mellitus; PTH, intact parathyroid hormone; nox-PTH, nonoxidized parathyroid hormone; FGF-23, fibroblast growth factor 23; rU/ml, relative units per ml; sKlotho, soluble klotho; vit., vitamine; ACE-I, angiotensin-converting enzyme inhibitor; At1A, angiotensin-II-receptor-subtype-1-antagonists.